Alexander C. Lewis

North Terrace
Adelaide, SA 5001, Australia

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications

Inhibition of heme biosynthesis triggers cuproptosis in acute myeloid leukemia.

Inhibition of heme biosynthesis triggers cuproptosis in acute myeloid leukemia.

Journal: Cell
Published: June 17, 2024

Inhibition of mutant IDH1 promotes cycling of acute myeloid leukemia stem cells.

Inhibition of mutant IDH1 promotes cycling of acute myeloid leukemia stem cells.

Journal: Cell reports
Published: March 07, 2022

Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma.

Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma.

Journal: Leukemia
Published: November 23, 2021

The sphingosine 1-phosphate receptor 2/4 antagonist JTE-013 elicits off-target effects on sphingolipid metabolism.

The sphingosine 1-phosphate receptor 2/4 antagonist JTE-013 elicits off-target effects on sphingolipid metabolism.

Journal: Scientific reports
Published: September 27, 2021

Inhibition of pyrimidine biosynthesis targets protein translation in acute myeloid leukemia.

Inhibition of pyrimidine biosynthesis targets protein translation in acute myeloid leukemia.

Journal: EMBO molecular medicine
Published: September 23, 2021

Ceramide-induced integrated stress response overcomes Bcl-2 inhibitor resistance in acute myeloid leukemia.

Ceramide-induced integrated stress response overcomes Bcl-2 inhibitor resistance in acute myeloid leukemia.

Journal: Blood
Published: July 09, 2021

Author Correction: Targeting sphingolipid metabolism as an approach for combination therapies in haematological malignancies.

Author Correction: Targeting sphingolipid metabolism as an approach for combination therapies in haematological malignancies.

Journal: Cell death discovery
Published: July 06, 2021

Publisher Correction: ROCK-mediated selective activation of PERK signalling causes fibroblast reprogramming and tumour progression through a CRELD2-dependent mechanism.

Publisher Correction: ROCK-mediated selective activation of PERK signalling causes fibroblast reprogramming and tumour progression through a CRELD2-dependent mechanism.

Journal: Nature cell biology
Published: June 06, 2020

Non-genetic heterogeneity, altered cell fate and differentiation therapy.

Non-genetic heterogeneity, altered cell fate and differentiation therapy.

Journal: EMBO molecular medicine
Published: May 05, 2020

Clinical MDR1 inhibitors enhance Smac-mimetic bioavailability to kill murine LSCs and improve survival in AML models.

Clinical MDR1 inhibitors enhance Smac-mimetic bioavailability to kill murine LSCs and improve survival in AML models.

Journal: Blood advances
Published: January 31, 2020

Kelch-like protein 5-mediated ubiquitination of lysine 183 promotes proteasomal degradation of sphingosine kinase 1.

Kelch-like protein 5-mediated ubiquitination of lysine 183 promotes proteasomal degradation of sphingosine kinase 1.

Journal: The Biochemical journal
Published: March 30, 2019

ROCK-mediated selective activation of PERK signalling causes fibroblast reprogramming and tumour progression through a CRELD2-dependent mechanism.

ROCK-mediated selective activation of PERK signalling causes fibroblast reprogramming and tumour progression through a CRELD2-dependent mechanism.

Journal: Nature cell biology
Published: February 07, 2019
Showing 1-12 of 15

Last Updated: 09/26/2026